CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Acrivon Therapeutics, Inc. (ACRV) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Acrivon Therapeutics, Inc. (ACRV)

Pharmaceutical Preparations · market cap $89M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-11-06
Acquisition
Pipeline
2
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
Acrivon Therapeutics (ACRV) is a 75-employee clinical-stage oncology company with two Phase 2 assets in our data: lead ACR-368 in endometrial adenocarcinoma and ACR-2316 in specific advanced solid tumors. The stock trades around $1.72 for a ~$74M market cap, against $41.4M of cash and no debt, so implied enterprise value is roughly $33M. The next two data events in our calendar are estimated for mid-2027.
The catalyst path
  • 2026-11-06Acquisitionimp 6/10
  • 2026-11-12 (est.)Earningsimp 5/10
  • 2027-05-30 (est.)Phase 2 · ACR-368imp 7/10
  • 2027-08-12 (est.)Phase 2 · ACR-2316imp 7/10
Pipeline
AssetPhaseIndication
ACR-2316Phase 2Specific Advanced Solid Tumors
ACR-368Phase 2Endometrial Adenocarcinoma
Price & technical context
3-month
-9.2%
6-month
-22.7%
12-month
-27.0%
52-wk range
$1.29–$3.01
vs 50-day MA
-17.2%
vs 200-day MA
-10.9%
Realized vol
89.5%
Max drawdown
-87.7%

Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for ACRV (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.